Company: ERAS
Filing Date: 2025-03-20
Form Type: 10-K
Source: 0000950170-25-042682
Chunk: 100

Company: Erasca, Inc.
Filing Date: 2025-03-20
Form: 10-K
Item: Item 16
Chunk 100
---
par value; 80,000,000 shares authorized at December 31, 2024 and 2023; no shares issued and outstanding at December 31, 2024 and 2023

    —

    —

    Common stock, $0.0001 par value; 800,000,000 shares authorized at December 31, 2024 and 2023; 283,218,344 shares issued and outstanding at December 31, 2024; 151,462,103 and 151,090,227 shares issued and outstanding at December 31, 2023, respectively

    28

    15

    Additional paid-in capital

    1,190,729

    922,607

    Accumulated other comprehensive income

    405

    77

    Accumulated deficit

    (767,663
    )

    (606,013
    )

    Total stockholders' equity

    423,499

    316,686

    Total liabilities and stockholders' equity
     
    $
    502,526

    $
    395,297

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Erasca, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

    Year Ended December 31,

    2024

    2023

    Operating expenses:

    Research and development
     
    $
    115,359

    $
    103,821

    In-process research and development

    22,500

    —

    General and administrative

    41,728

    37,704

    Total operating expenses

    179,587

    141,525

    Loss from operations

    (179,587
    )

    (141,525
    )

    Other income (expense)

    Interest income

    20,093

    16,712

    Other expense, net

    (2,156
    )

    (229
    )

    Total other income (expense), net

    17,937

    16,483

    Net loss
     
    $
    (161,650
    )
     
    $
    (125,042
    )

    Net loss per share, basic and diluted
     
    $
    (0.69